Kenvue Inc. Common Stock vs Tilray Brands Inc — how do they compare? Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Kenvue Inc. Common Stock is far larger — about 64.2× Tilray Brands Inc's market cap, and Kenvue Inc. Common Stock pays a 4.74% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| KVUE | TLRY | |
|---|---|---|
Market Cap | $34.06B | $530.54M |
Volume | 23,267,228 | 9,099,075 |
Sector | Consumer Staples | Health |
52-Week High | $19.83 | $21.00 |
52-Week Low | $14.11 | $3.57 |
Enterprise Value | $41.56B | $684.46M |
Dividend Yield | 4.74% | — |
Typical Hold Time | — | 31 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLRY trades at $3.54, down 4.71% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows negative technical momentum with consecutive earnings misses and widening losses despite revenue growth. Recent financials reveal a net loss of $2.19B for 2025, though analyst consensus maintains a $65.01 price target with 25% buy ratings. Business developments include new product launches and leadership changes under Tilray's expanded beverage portfolio.
Outlook remains challenged by profitability concerns and high debt, but potential cannabis regulatory shifts could catalyze recovery. Investment opportunity hinges on execution improvement and market expansion, while risks include sustained cash burn and competitive pressures in the cannabis sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →